Form 8-K · Current Report · Filed 2025-02-06
Illumina Reports Q4 and FY 2024 Financial Results
Illumina, Inc. reported its financial results for the fourth quarter and fiscal year 2024. The company achieved core revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023, and $4.3 billion for FY 2024, down 2% from FY 2023. GAAP operating margin for Q4 2024 was 15.8%, and non-GAAP operating margin was 19.7%. GAAP diluted EPS for Q4 2024 was $0.73, and non-GAAP diluted EPS was $0.95. For fiscal year 2025, the company expects core revenue growth in the low single digits and a non-GAAP operating margin of approximately 23%.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001110803-25-000014
- CIK
- 0001110803
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$124.68
Next session
-10.9%
Since filing
+64.5%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Exhibits (1)
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.